Visão geral da empresa
A biotechnology firm dedicated to the discovery, development, and commercialization of redosable therapeutics, Generation Bio Co. focuses on reprogramming T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells through the use of cell-targeted lipid nanoparticles. The company operates within the Healthcare sector, specifically the Biotechnology industry, a domain characterized by high innovation requirements and significant capital expenditure for research and development. According to the latest available data, the entity maintains a market capitalization of $35.98M, reports annual revenue of $15.27M, and employs a workforce of 115 individuals. These financial metrics indicate a small-cap biotechnology enterprise with limited revenue generation relative to its market valuation, suggesting the company is likely in a phase where future commercialization potential is valued more highly than current cash flows. The substantial disparity between the market cap and the revenue base implies that the stock price is driven primarily by expectations of future therapeutic approvals and commercial success rather than established profitability.
Saúde financeira
The company reported a revenue of $15.27M over the trailing twelve months, yet this generated a net income of -$62,627,000 and an EBITDA of -$76,380,000, revealing a cost structure where expenses vastly exceed income. The free cash flow stands at -$40,196,752, indicating a significant cash burn rate that limits immediate financial flexibility and necessitates reliance on existing cash reserves or external financing. Gross margin is reported at -212.2%, operating margin at -2020.0%, and profit margin at 0.0%, figures that collectively demonstrate severe underpricing of costs relative to revenue or accounting adjustments typical in early-stage biotechnology development. The company holds $89.62M in cash against $26.10M in debt, resulting in a debt-to-equity ratio of 51.61, which suggests a balance sheet that is heavily leveraged relative to its equity base despite the high absolute cash balance. The current ratio of 4.44 indicates strong short-term liquidity, as current assets are more than four times current liabilities, providing a buffer to meet obligations. Return on equity is -80.8% and return on assets is -27.4%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the company.
Avaliação de valorização
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -3.99, a divergence that implies the market is pricing in future earnings that are expected to turn positive or that current valuation models rely on non-earnings-based multiples. The price-to-book ratio is 0.71, indicating that the market values the company at a discount to its book value, which often occurs in capital-intensive industries where assets may not be fully reflected on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.36 and an EV/EBITDA of 0.36 suggest the company is valued based on sales multiples or enterprise value relative to operating cash flow rather than traditional earnings multiples. The 52-week high is $7.60 and the 52-week low is $3.00, placing the current trading price within a range that reflects significant volatility typical of biotechnology stocks. The beta value of 2.01 indicates that the stock is expected to be twice as volatile as the broader market, meaning price swings will be amplified compared to large-cap indices.
Growth & Income
Revenue growth year-over-year is -78.9%, while earnings growth is N/A due to the lack of positive earnings history, implying that the company is currently contracting in terms of sales rather than expanding. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it is assumed that the organization reinvests its limited cash flow into research and development rather than distributing income to shareholders. The negative revenue growth combined with the absence of dividend income creates a profile focused entirely on capital appreciation potential rather than income generation or stability. Overall, the growth and income profile is characterized by high risk and a complete absence of current earnings or dividend distributions, relying solely on the successful commercialization of its redosable therapeutics pipeline.